Although early detection and treatment of cystic fibrosis-related diabetes (CFRD) can lead to significant clinical improvements and prolong life, rates of screening are poor likely due to the burdensome nature of oral glucose tolerance testing (OGTT). The investigators propose to assess the feasibility and accuracy of two screening tools, continuous glucose monitoring (CGM) and a home OGTT kit (GTT@home). If this pilot study reveals acceptable accuracy of either device, this study will allow for future studies exploring home-based OGTT screening.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose
Timeframe: Fasting glucose before OGTT
Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose
Timeframe: 1 hour mark in OGTT
Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose
Timeframe: 2 hour mark in OGTT